EyePoint plummets on pivotal data for main drug

1 source ·1 article ·Aug 17, 15:31 UTC Advanced Micro Devices EyePoint

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Aug 17, 15:31 UTC

EyePoint plummets on pivotal data for main drug

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

EyePoint plummets on pivotal data for main drug

EyePoint plummets on pivotal data for main drug →

EyePoint plummets on pivotal data for main drug